Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Corporate Highlights
On Track to Dose First Patient in Pivotal Phase 3 Trial of Pegzilarginase for ARG1-D in Q2 of 2019
Initiated IND-Enabling Studies for New Pipeline Programs
Progress with Pegzilarginase Cancer Indication-Phase 2 Combination Study Initiated
Gross Proceeds of $69 Million from February 2019 Public Offering Extends Cash Runway Through Q1 of 2021
Company to Host Conference Call and Webcast Today at 4:30 p.m. ET
AUSTIN, Texas, March 07, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today reported its fourth quarter and full year 2018 financial results and provided corporate highlights.
“2018 was a very successful year for the company,” said Anthony G. Quinn, M.B. Ch.B, Ph.D., president and chief executive officer of Aeglea. “We made substantial progress with our clinical programs for pegzilarginase in Arginase 1 Deficiency (ARG1-D) and oncology, leveraged our unique drug hunting capabilities to generate new pipeline programs for cystinuria and homocystinuria and strengthened Aeglea’s balance sheet. As we look to 2019, the Company is well positioned to advance our clinical and research programs, as well as to leverage our human enzyme design capabilities to address other diseases with significant unmet medical need.”
Pegzilarginase in Arginase 1 Deficiency
-- Completed dosing of Phase 1/2 trial in February 2019, with 14 out of 16 enrolled patients completing eight weeks of repeat dosing. Clinical data from this trial, which informed the design of the Phase 3 PEACE (Pegzilarginase Effect on Arginase 1 Deficiency Clinical Endpoints) trial protocol, included the demonstration that pegzilarginase is effective in reducing plasma arginine levels with accompanying improvements in important disease-related abnormalities. Insights from standardized clinical assessments and feedback from physicians and caregivers also established the value of mobility and adaptive behavior assessments in capturing the clinical benefits of pegzilarginase. Additionally, pegzilarginase appeared safe and well tolerated. Aeglea expects to report Phase 1/2 data at an oral presentation at the Society for Inherited Metabolic Disorders (SIMD) annual meeting being held April 6-9 in Seattle, Washington. -- In December 2018, the Company announced the design of its single, global pivotal Phase 3 PEACE trial based on input from the U.S. Food and Drug Administration (FDA) and the European Medicine Agency (EMA). Pegzilarginase is believed to be the first-ever investigative therapy for patients with ARG1-D that addresses the high arginine levels that are the key drivers of this devastating disease. PEACE is a global, randomized, double-blind, placebo-controlled trial designed to assess the effects of treatment with pegzilarginase versus placebo over 24 weeks with a primary endpoint of plasma arginine reduction. Secondary endpoints will include mobility and adaptive behavior as assessments of clinically meaningful effects, in addition to safety and pharmacokinetics. Aeglea expects to dose the first patient in the PEACE trial in the second quarter of 2019 and anticipates top-line data will be available in the first quarter of 2021. -- Pediatric review voucher (PRV) eligible given receipt of rare pediatric disease designation from FDA for treatment of ARG1-D.
Pegzilarginase in Cancer
-- Completed the Phase 1b safety evaluation and dose selection for pegzilarginase in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy. This trial is designed to assess the safety and efficacy of pegzilarginase with KEYTRUDA in patients with extensive disease small cell lung cancer (SCLC) who have relapsed or progressive disease after platinum-based chemotherapy. - Initiated enrollment in the open label Phase 2 study of pegzilarginase in combination with KEYTRUDA in December 2018. This trial is designed to assess the safety and efficacy of pegzilarginase with KEYTRUDA in patients with extensive disease SCLC, with top-line data anticipated in the first half of 2020. - 16 patients were enrolled across three cohorts in Phase 1b, with selection of the Phase 2 dose of 0.27 mg/kg/week of pegzilarginase in combination with KEYTRUDA. Of nine patients in the Phase 1b trial treated with 0.27 mg/kg/week, three patients had stable disease (SD) at 9 weeks and one partial response (PR) was observed. Three patients remain on treatment. The safety profile was consistent with pegzilarginase monotherapy observations. -- Completed enrollment in the single agent Phase 1 cohort expansions investigating pegzilarginase in patients with heavily pre-treated cutaneous melanoma, uveal melanoma and SCLC. In October 2018, the Company presented interim clinical data demonstrating monotherapy anti-tumor activity with pegzilarginase in the advanced melanoma cohorts. For SCLC, no objective responses and no new safety findings were observed in the 13 heavily-pretreated SCLC patients in the single-agent expansion arm, which completed enrollment in December 2018.
AEB4104 for Homocystinuria
-- Initiated IND-enabling activities of AEB4104 for homocystinuria, a severe, progressive, rare genetic disease with significant unmet medical need. In homocystinuria disease models, AEB4104 lowered plasma homocysteine and homocystine levels with improved survival and correction of disease-related abnormalities. Aeglea is progressing manufacturing, pharmacology and other IND-enabling activities to support preclinical toxicology studies and advancement towards clinical trials. The Company anticipates filing an IND or CTA in the first quarter of 2020.
AEB5100 for Cystinuria
-- Initiated IND-enabling activities for AEB5100, a modified human enzyme approach with a unique specificity for degrading cystine, for the treatment of patients with cystinuria. In a cystinuria disease model, AEB5100 lowered blood levels of cystine, decreased the amount of cystine in the urine and reduced both cystine crystal and kidney stone formation. Aeglea is progressing manufacturing, pharmacology and other IND-enabling activities to support preclinical toxicology studies and advancement towards clinical trials. The Company anticipates filing an IND or CTA in the second half of 2020.
-- In February 2019, the Company closed an underwritten public offering, which resulted in total gross proceeds of $69 million, of 4.6 million shares of its common stock at a price to the public of $8.00 per share, including 1.1 million shares pursuant to the underwriters’ exercise in full of their option to purchase additional shares of common stock. In addition, and in lieu of common stock, Aeglea sold to certain investors pre-funded warrants to purchase up to an aggregate 4.0 million shares of common stock at a purchase price of $7.9999 per warrant, which represents the per share public offering price for the common stock less the $0.0001 per share exercise price for each such pre-funded warrant. -- Russell Cox, who has served as an Aeglea director since June 2015, assumed the position of chairman of the board in 2019. Armen Shanafelt, Ph.D., who served as chairman since February 2014, will continue as a director. -- Leslie Sloan, Ph.D., was appointed chief operating officer, a new position within Aeglea. Dr. Sloan was previously senior vice president of operations and will continue to report to the CEO. Dr. Sloan will be responsible for a number of key areas at the company, including operational management of drug development, regulatory affairs, manufacturing, commercial readiness and program management.
-- Aeglea will provide an oral presentation titled “Sustained Reductions in Plasma Arginine Following Pegzilarginase Administration in Patients with Arginase-1 Deficiency are Accompanied by Improvements in Mobility and Adaptive Behavior” on Sunday, April 7th from 4:00-4:15 p.m. PT at the Society for Inherited Metabolic Disorders (SIMD) annual meeting being held April 6-9 in Seattle, Washington. -- Aeglea will present at the following conferences, with details regarding the date and time of the presentations and webcasts announced prior to the events. - H.C. Wainwright & Co., Global Life Sciences Conference to be held April 7- 9th in London, England - 18th Annual Needham Healthcare Conference to be held April 9-10th in New York, NY
Fourth Quarter and Full Year 2018 Financial Results
As of December 31, 2018, Aeglea had available cash, cash equivalents and marketable securities of $74.5 million, which excludes approximately $69.0 million in gross proceeds from a public offering to new and existing shareholders in February 2019. Based on Aeglea’s current operating plan, and taking into account the $69.0 million raised in February 2019, management believes it has sufficient capital resources to fund anticipated operations through the first quarter of 2021.
Grant revenues were the result of a $19.8 million research grant received from the Cancer Prevention and Research Institute of Texas (CPRIT). The grant contract concluded in May 2018 with the full $19.8 million in grant proceeds collected and recognized as revenue over the life of the award. Aeglea did not recognize any grant revenues in the fourth quarter of 2018, compared with $1.5 million in the fourth quarter of 2017. Grant revenues of $3.9 million were recognized in the year ended December 31, 2018, compared with $5.2 million in the year ended December 31, 2017.
Research and development expenses totaled $11.8 million for the fourth quarter of 2018, compared with $5.8 million for the fourth quarter of 2017. The increase was primarily due to additional clinical development activity of Aeglea’s lead product candidate, pegzilarginase, and a ramp-up in manufacturing activities for pegzilarginase. Aeglea completed and exceeded enrollment in its Phase 1/2 clinical trial in patients with Arginase 1 Deficiency, completed enrollment of three single-agent cohort expansions in a Phase 1 clinical trial for advanced solid tumor patients, and completed enrollment of a Phase 1 combination trial in patients with small cell lung cancer.
Research and development expenses totaled $36.7 million for the year ended December 31, 2018, compared with $22.8 million for the year ended December 31, 2017. The increase was primarily associated with advancing the clinical development of pegzilarginase and expanding our internal clinical development capabilities and research laboratory. Aeglea completed and exceeded enrollment in its Phase 1/2 clinical trial for pegzilarginase in patients with Arginase 1 Deficiency. Additionally, the Company initiated and completed enrollment of three single-agent cohort expansions for the Phase 1 trial in patients with advanced solid tumors and completed enrollment of its Phase 1 combination trial in patients with small cell lung cancer.
General and administrative expenses totaled $3.5 million for the fourth quarter of 2018, compared with $2.3 million for the fourth quarter of 2017. This increase was primarily due to additional employee headcount, compensation, and consulting costs.
General and administrative expenses totaled $12.6 million for the year ended December 31, 2018, compared with $10.1 million in the year ended December 31, 2017. This increase was primarily due to additional employee headcount and compensation to support Company growth.
Net loss totaled $14.9 million and $6.5 million for the fourth quarter of 2018 and 2017, respectively, with non-cash stock compensation expense of $1.4 million and $0.7 million for the fourth quarter of 2018 and 2017, respectively. Net loss totaled $44.3 million and $27.2 million for the years ended December 31, 2018 and 2017, respectively, with non-cash stock compensation expense of $4.3 million and $2.5 million for the years ended December 31, 2018 and 2017, respectively.
Conference Call & Webcast Details
Aeglea will hold a conference call on Thursday, March 7, 2019 at 4:30 p.m. ET. To access the live conference call via phone, please dial +1 (877) 709-8155 (toll free) within the United States, or +1 (201) 689-8881 internationally. A replay of the call will be available through March 14, 2019 by dialing +1 (877) 660-6853 within the United States or +1 (201) 612-7415 internationally. The conference ID is 13688006.
To access the live and archived webcast of the presentation, please visit the Presentation & Events section of the Aeglea BioTherapeutics investor relations website. Please connect to the website at least 15 minutes prior to the presentation to allow for any software download that may be necessary.
About Pegzilarginase in Arginase 1 Deficiency
Pegzilarginase is an enhanced human arginase that enzymatically depletes the amino acid arginine. Aeglea is developing pegzilarginase for the treatment of patients with Arginase 1 Deficiency, a rare debilitating disease presenting in childhood with persistent hyperargininemia, severe progressive neurological abnormalities and early mortality. Pegzilarginase is intended for use as an enzyme replacement therapy in patients to reduce elevated blood arginine levels. Aeglea’s interim Phase 1/2 data demonstrated clinical improvements and rapid and sustained lowering of plasma arginine in Arginase 1 Deficiency patients.
About AEB4104 in Homocystinuria
AEB4104 is a novel recombinant human enzyme that degrades the amino acid homocysteine and its related homocystine dimer. Aeglea is developing AEB4104 for the treatment of patients with cystathionine beta synthase (CBS) deficiency, also known as Classical Homocystinuria. Homocysteine accumulation plays a key role in multiple progressive and serious disease-related complications, including thromboembolic vascular events; skeletal abnormalities including severe osteoporosis; developmental delay and intellectual disability; lens dislocation and severe myopia. AEB4104 is intended to lower the abnormally high blood levels of homocysteine to the normal range in patients with homocystinuria. Preclinical data demonstrated that AEB4104 improved important disease-related abnormalities and survival in a mouse model of homocystinuria.
About AEB5100 in Cystinuria
AEB5100 is a novel recombinant human enzyme that degrades cystine and the parent amino acid cysteine. Aeglea is developing AEB5100 for the treatment of patients with cystinuria, a rare genetic disease characterized by frequent and recurrent kidney stone formation from an early age. Affected individuals have severe symptoms, frequent hospital admissions, a requirement for multiple procedural interventions and an increased risk of both hypertension and chronic kidney disease. Cystinuria occurs due to genetic mutations in amino acid transporters that lead to increased amounts of cystine in the urine. The high urine cystine concentrations leads to kidney stones formation. Preclinical data demonstrated that AEB5100 lowered blood levels of cystine and cysteine, decreased the amount of cystine in the urine and reduced kidney stone formation in a mouse model of cystinuria.
About Pegzilarginase in Cancer
Pegzilarginase is an enhanced human arginase that enzymatically degrades the amino acid arginine. In some cancers, tumor cells are unable to produce specific amino acids and must acquire them from the blood, making the tumor cells susceptible to starvation through depletion of those amino acids. Aeglea is developing pegzilarginase to exploit vulnerabilities in some cancers that lead to an increased dependency on extracellular arginine. Pegzilarginase targets these arginine dependent cancers by depleting blood arginine levels to below the normal range. Preclinical data demonstrated that the resulting arginine starvation inhibits proliferation, induces cell death, increases turnover of cell components and promotes anti-tumor immune responses. The Company’s Phase 1 data in advanced solid tumors demonstrated that pegzilarginase was well tolerated at doses that produced marked and sustained reductions in blood arginine levels below the normal range.
About Aeglea BioTherapeutics Aeglea is a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer. Aeglea is developing pegzilarginase, its lead investigational therapy, for the treatment of Arginase 1 Deficiency, as monotherapy in arginine-dependent cancers and in combination with an immune checkpoint inhibitor for small cell lung cancer. In addition, Aeglea has an active research pipeline of other human enzyme-based approaches in both therapeutic areas. For more information, please visit http://aegleabio.com.
Safe Harbor / Forward-Looking Statements
This press release contains “forward-looking” statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will” and similar references to future periods. These statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from what we expect. Examples of forward-looking statements include, among others, statements we make regarding our cash forecasts, the timing and success of our clinical trials and related data, the timing of announcements and updates relating to our clinical trials and related data, our ability to enroll patients into our clinical trials, success in our collaborations and the potential therapeutic benefits and economic value of our lead product candidate or other product candidates. Further information on potential risk factors that could affect our business and its financial results are detailed in our most recent Annual Report on Form 10-K for the year ended December 31, 2018 filed with the Securities and Exchange Commission (SEC), and other reports as filed with the SEC. We undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.
Media Contact: David CalusdianSharon Merrill Associates617.542.5300AGLE@investorrelations.com
Investor Contact: Joey Perrone Director, Finance & Investor RelationsAeglea BioTherapeutics email@example.com
Aeglea BioTherapeutics, Inc.Consolidated Balance Sheets
(In thousands, except share and per share amounts)
December 31, ----------------------- 2018 2017 ---------- --------- ASSETS CURRENT ASSETS Cash and cash equivalents $ 22,461 $ 12,817 Marketable securities 52,052 37,482 Accounts receivable - grant — 3,078 Prepaid expenses and other current assets 2,158 1,614 - -------- - ------- Total current assets 76,671 54,991 Property and equipment, net 1,018 854 Other non-current assets 50 232 - -------- - ------- TOTAL ASSETS $ 77,739 $ 56,077 - -------- - ------- LIABILITIES AND STOCKHOLDERS’EQUITY CURRENT LIABILITIES Accounts payable $ 663 $ 389 Deferred revenue — 20 Accrued and other current liabilities 9,576 5,220 - -------- - ------- Total current liabilities 10,239 5,629 Other non-current liabilities 72 111 - -------- - ------- TOTAL LIABILITIES 10,311 5,740 - -------- - ------- STOCKHOLDERS’ EQUITY Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of December 31, 2018 and December 31, 2017; no shares issued and outstanding as of December 31, — — 2018 and December 31, 2017 Common stock, $0.0001 par value; 500,000,000 shares authorized as of December 31, 2018 and December 31, 2017; 24,140,097 shares and 16,670,188 shares issued and 2 2 outstanding as of December 31, 2018 and December 31, 2017, respectively Additional paid-in capital 184,314 122,950 Accumulated other comprehensive loss (27 ) (102 ) Accumulated deficit (116,861 ) (72,513 ) - -------- - ------- TOTAL STOCKHOLDERS’ EQUITY 67,428 50,337 - -------- - ------- TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY $ 77,739 $ 56,077 - -------- - -------
Aeglea BioTherapeutics, Inc.Consolidated Statements of Operations
(In thousands, except share and per share amounts)
Year Ended December 31, ------------------------------------------- 2018 2017 2016 ------------ ------------ ----------- Revenues: Grant $ 3,888 $ 5,205 $ 4,628 Operating expenses: Research and development 36,719 22,815 18,143 General and administrative 12,632 10,066 8,391 - ---------- - ---------- - --------- Total operating expenses 49,351 32,881 26,534 - ---------- - ---------- - --------- Loss from operations (45,463 ) (27,676 ) (21,906 ) Other income (expense): Interest income 1,172 482 244 Other expense (57 ) (42 ) (36 ) - ---------- - ---------- - --------- Total other income 1,115 440 208 - ---------- - ---------- - --------- Net loss $ (44,348 ) $ (27,236 ) $ (21,698 ) - ---------- - ---------- - --------- Net loss per share, basic and diluted $ (2.13 ) $ (1.80 ) $ (2.22 ) Weighted-average common shares outstanding, basic and diluted 20,822,560 15,128,192 9,791,728